MICHÁLEK, Jaroslav, Tomáš BÜCHLER and Roman HÁJEK. T Lymphocyte Therapy of Cancer. Physiological Research. Praha: Institute of Physiology,Academy of Sciences of the Czech Republic, 2004, vol. 53, No 53, p. 463-469. ISSN 0862-8408.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name T Lymphocyte Therapy of Cancer
Name in Czech T- Lymfocytární terapie nádorů
Authors MICHÁLEK, Jaroslav (203 Czech Republic, guarantor), Tomáš BÜCHLER (703 Slovakia) and Roman HÁJEK (203 Czech Republic).
Edition Physiological Research, Praha, Institute of Physiology,Academy of Sciences of the Czech Republic, 2004, 0862-8408.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30102 Immunology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.140
RIV identification code RIV/00216224:14110/04:00011104
Organization unit Faculty of Medicine
UT WoS 000224572900001
Keywords in English T lymphocyte; Cancer; Therapy
Tags cancer, T lymphocyte, THERAPY
Changed by Changed by: Jana Křivá, učo 142614. Changed: 23/6/2009 09:17.
Abstract
The rationale for the use of T lymphocytes to fight cancer is the immunogenicity of tumor cells.T cells are capable to recognize and finally to kill tumor cells.Adoptiveč cell transfer therapies provide the opportunity to overcome tolerogenic mechanisms by enabling the selection and activation of highly reactive T cell subpopulations and bymanipulation of the host environment into which the T cell are introduced. The aim of this article is to review the possibilities,limitations and recent clinical experience with this novel anticancer treatment,namely with adoptive immunotherapy using antigen-specific T cells.
Abstract (in Czech)
Princip použití T lymfocytů v boji s nádorovými buňkami- je imunogenicita. T buňky jsou schopné rozpoznat a úplně zničit nádorové buňky.Adoptivní buněčné transferové terapie umožňují překonat mechanismy tolerance,které umožují selekci a aktivaci vysoce reaktivních T buněčných subpopulací a ovlivnění hostitelskéhoprostředí.Přínos tohoto článku je zhodnotit možnosti ,limitace a současné klinické zkušenosti, které tuto novou protinádorovou léčbu a to zejména s adoptivní imunoterapií využívajících antigen-specifických T buněk.
Links
MSM 141100003, plan (intention)Name: Zevní prostředí - karcinogeneze - onkologie
Investor: Ministry of Education, Youth and Sports of the CR, Environment - carcinogenesis - oncology
PrintDisplayed: 22/7/2024 15:28